Registration and Renewal Fees for Medical Devices in Morocco

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

The official fees for medical device registration in Morocco are very low, a distinctive feature of its market-access system. The consistent industry figure is: MAD 1,000 (about USD 111) for new device registration and MAD 1,000 for renewal; MAD 500 (about USD 56) for new in vitro diagnostic reagent registration and MAD 500 for renewal. GRZAN must flag clearly: these amounts come from the consistent accounts of several international registration agencies, and this verification did not obtain an independently numbered official Moroccan tariff text, so they are treated as a practical estimate and must not serve as a quotation basis. Budgeting decisions should always confirm the figures against the current tariff text before they are committed.

2. Legal basis

InstrumentReference numberPublication dateProvisions
Medical Devices Law (Loi n° 84-12)Dahir n° 1-13-9030 August 2013Article 14 (applications must be accompanied by a dossier; payment is a procedural step)
Implementing decree of Law No. 84-12 (Décret n° 2-14-607)Décret n° 2-14-60718 September 2014Article 4 (review period); Article 6 (5-year validity and renewability)
Current Moroccan tariff textNo single official reference obtained (this verification)—Registration and renewal fee rates

Practical estimate: the MAD 1,000 (devices) and MAD 500 (IVD) amounts, together with the corresponding US dollar conversions of about 111 and 56 dollars, come from the consistent accounts of several international registration agencies and industry material. GRZAN did not locate a numbered official Moroccan tariff text with a publication date, and therefore does not cite them as a regulatory basis. Before formal budgeting, the current tariff text must be checked with AMMPS or the certificate-holding establishment.

3. Expert insights

Insight 1: Low official fees do not mean low total cost. The official fee is only a small fraction of total project cost. The real cost concentrates in three places: the service fees of the certificate-holding establishment, French translation with notarisation and legalisation, and the personnel investment in dossier preparation and deficiency responses. Treating MAD 1,000 as evidence that Moroccan registration is cheap seriously underestimates the project budget. A realistic cost model lists the official fee as one line among several, and usually the smallest one, with the local partner’s services and documentation work dominating the total.

Insight 2: The timing of payment affects when the review clock starts. Arrêté n° 2855-15 requires the administrative file to include a copy of the payment receipt, while Article 4 of Décret n° 2-14-607 sets a 120-day review period running from submission of the complete dossier. A missing payment receipt makes the dossier incomplete and the clock does not start. Payment therefore needs to be scheduled before submission, not after, and the receipt must be physically included in the file rather than promised in a cover letter.

Insight 3: Renewal also requires payment and a dossier. Article 6 provides that the registration certificate is valid for 5 years and renewable. Renewal is not an automatic extension procedure: the practical estimate shows that renewal requires the certificate-holding establishment to submit a formal application with a dossier, at a fee equal to the new registration fee. Budget holders should treat year 5 of every certificate as carrying a full renewal workload, not a nominal formality, and plan partner resources accordingly.

Insight 4: The fee difference between IVD and devices reflects two different channels. The gap between MAD 500 and MAD 1,000 corresponds to two different legal channels — Law No. 11-08 and Law No. 84-12. This is a further reminder that mixed product lines must be costed separately. A portfolio containing both devices and IVD reagents cannot be budgeted on a single per-product fee assumption; the two fee lines, the two dossier regimes, and the two renewal calendars all diverge and must be tracked apart.

Insight 5: Currency conversions drift. The figures of USD 111 and USD 56 are conversions at a particular point in time. Formal budgets should be denominated in Moroccan dirhams and converted at the current rate, avoiding exchange losses caused by quoting externally in dollars. Contracts with local partners should state the currency and the exchange-rate mechanism explicitly, so that a moving rate does not silently alter the economics of a multi-year renewal programme.

4. Practical recommendations

  1. Budget on four lines: official fee, service fee, translation and legalisation, and personnel. Keep the official fee as a separate line, and re-confirm the amount with the certificate-holding establishment before quoting it.
  2. Treat the payment receipt as a completeness requirement of the dossier. List the copy of the payment receipt as its own item in the pre-submission self-check.
  3. Front-load renewal fees into the 5-year budget. Reserve the renewal official fee and service fees in the year 5 budget of each certificate.
  4. Quote externally in Moroccan dirhams. Use dollar conversions only as reference, and state the exchange-rate clause in contracts.
  5. Check the tariff text before every project start. Add the fee check to the project initiation checklist; never carry over amounts from a previous project.

5. Verification checklist

  • □ The current tariff text has been checked with AMMPS or the certificate-holding establishment
  • □ The official fee amounts are marked as a practical estimate with their source nature explained
  • □ The budget covers official fees, service fees, translation and legalisation, and personnel
  • □ The copy of the payment receipt is listed in the dossier completeness self-check
  • □ Renewal fees are included in the year 5 budget
  • □ External quotations are denominated in dirhams with an exchange-rate clause agreed
  • □ IVD and device fee lines have been calculated separately

Regulatory information verified as of 30 October 2026

GRZAN supports medical device manufacturers entering the Moroccan market with full cost budgeting for registration, renewal, and maintenance obligations, including official fee verification, local partner fee negotiation, and translation and legalisation planning. For support on the requirements described above, contact info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail